+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying WIN378, a long-acting medicine, in adults with moderate to severe chronic obstructive pulmonary disease COPD. WIN378 targets a protein called TSLP that causes lung inflammation and may influence COPD symptoms and control. This Phase 2a trial aims to find the right dose by assessing safety, how the body processes the medicine, and its effects on markers of inflammation, lung function, and disease control. Participants will receive subcutaneous injections of WIN378 at different doses or a placebo over a 24-week treatment period while continuing their usual COPD therapies. The study is randomized, double-blind, and placebo-controlled, ensuring a thorough comparison of effects. The treatment phase lasts 24 weeks, followed by monitoring up to 36 weeks for safety and drug concentration in the blood. During the study, participants will undergo lung function tests, blood tests, and exhaled breath analyses to assess inflammation and COPD control. Researchers will monitor vital signs, laboratory parameters, and any adverse events throughout the 36-week period. The trial also tracks the presence of antibodies against WIN378. Participants are involved in regular evaluations to help understand how the medicine works and its safety profile.

Age: 40Years - 80YearsAll GendersPhase 2
32 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, and pharmacokinetics of INM004 in children with Hemolytic Uremic Syndrome caused by Shiga toxin-producing Escherichia coli STEC-HUS. This study aims to assess how well INM004, when added to standard care, improves kidney function and reduces complications, mortality, and hospital stay in affected pediatric patients. Participants will be randomly assigned to receive either two doses of INM004, an Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin fragment, or two doses of a placebo solution. Each dose is given intravenously 24 hours apart, with infusion times adjusted based on body mass index. The study includes a 28-day acute phase and further assessments up to 90 days to monitor recovery and other health outcomes. During the study, children will undergo evaluations of kidney function, blood tests for markers of disease activity, and safety assessments. Researchers will measure the time to kidney function recovery as the primary outcome, along with mortality rates, dialysis needs, and hospital stay length. The trial lasts for at least 90 days, including close monitoring of health status and medication effects throughout this period.

Age: 9Months - 17YearsAll GendersPhase 3
52 locations